Heartland Advisors Inc. Invests $1.98 Million in Arcturus Therapeutics Holdings Inc. $ARCT

Heartland Advisors Inc. purchased a new stake in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 256,000 shares of the biotechnology company’s stock, valued at approximately $1,976,000.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Hennion & Walsh Asset Management Inc. grew its position in Arcturus Therapeutics by 206.5% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 240,303 shares of the biotechnology company’s stock valued at $1,473,000 after buying an additional 161,910 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. increased its stake in Arcturus Therapeutics by 12.9% during the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,288,935 shares of the biotechnology company’s stock valued at $17,671,000 after buying an additional 262,347 shares during the period. Byrne Asset Management LLC raised its position in shares of Arcturus Therapeutics by 4,412.5% during the 4th quarter. Byrne Asset Management LLC now owns 18,050 shares of the biotechnology company’s stock worth $111,000 after buying an additional 17,650 shares in the last quarter. Green Alpha Advisors LLC lifted its stake in shares of Arcturus Therapeutics by 31.9% in the 4th quarter. Green Alpha Advisors LLC now owns 28,282 shares of the biotechnology company’s stock worth $173,000 after acquiring an additional 6,839 shares during the period. Finally, Strs Ohio acquired a new stake in shares of Arcturus Therapeutics in the 1st quarter worth approximately $89,000. 94.54% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on ARCT. Wall Street Zen upgraded shares of Arcturus Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday. Weiss Ratings raised Arcturus Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, April 21st. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $24.25.

Arcturus Therapeutics Price Performance

Shares of ARCT stock opened at $6.05 on Monday. The stock has a 50-day simple moving average of $7.22 and a 200 day simple moving average of $7.48. Arcturus Therapeutics Holdings Inc. has a fifty-two week low of $5.85 and a fifty-two week high of $24.17. The stock has a market capitalization of $171.94 million, a P/E ratio of -2.15 and a beta of 2.37.

Arcturus Therapeutics (NASDAQ:ARCT) last released its earnings results on Friday, May 8th. The biotechnology company reported ($0.95) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.03) by $0.08. Arcturus Therapeutics had a negative return on equity of 36.55% and a negative net margin of 143.80%.The firm had revenue of $2.06 million for the quarter, compared to analyst estimates of $6.30 million. On average, sell-side analysts anticipate that Arcturus Therapeutics Holdings Inc. will post -3.99 earnings per share for the current year.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.